

COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the

RESEARCH REPORT



ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKETS, STRATEGIES AND TRENDS BY PATHOGEN AND TECHNOLOGY, WITH EXECUTIVE GUIDES AND CUSTOMIZATION. 2021 TO 2025





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the X-Ray market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

i. Antimicrobial Resistance - Strategic Situation Analysis & Impact of COVID-19	16
ii. Guide for Executives, Marketing, Sales and Business Development Staff	18
iii. Guide for Management Consultants and Investment Advisors	20
1. Introduction and Market Definition	21
1.1 The Growing Threat and Opportunity of Antimicrobial Resistance.....	22
1.2 Defining the Opportunity.....	25
1.2.1 Revenue Market Size	25
1.3 Methods and Sources	27
1.3.1 Authors	27
1.3.2 Sources	27
1.4 U.S. Antibiotic Markets - Perspective.....	28
1.4.1 U.S. Outpatient Use of Antibiotics	28
1.4.2 U.S. Pharmaceutical Spending	32
2. Overview of a Dynamic Market	34
2.1 Market Players – Roles & Impacts	35
2.1.1 Drug manufacturers - Larger/pharmaceutical.....	36
2.1.2 Drug manufacturers - Generic	37
2.1.3 Contract Research and Manufacturing	37
2.1.4 In Vitro Diagnostics Industry	38

2.1.5 Drug Marketing Companies	39
2.1.6 Biotechnology Companies	40
2.1.7 Regulatory Bodies	41
2.2 Understanding Antimicrobial Resistance	42
2.2.1 What is Antimicrobial Resistance (AMR).....	42
2.2.2 Bacteria and Other Microbes	43
2.2.3 The History of Antibiotics.....	49
2.2.4 The Role of Animal Husbandry.....	53
2.2.5 The Implications of Horizontal Transfer	54
2.2.6 The Threat of AMR.....	55
2.3 The Changing Road to New Antibiotics & Technologies.....	58
2.4 The Key Role of Diagnostics in AMR.....	60
3. The Market Opportunity of AMR.....	61
3.1 The Key Large Market Opportunities in AMR.....	62
3.1.1 Streptococcus Pneumoniae (DRSP).....	63
3.1.2 Campylobacter (DRC).....	66
3.1.3 Clostridium Difficile (CD).....	69
3.1.4 Staphylococcus aureus (MRSA).....	72
3.1.5 Neisseria gonorrhoeae (DRNG)	75
3.1.6 Salmonella (DRNTS)	78
3.2 Diagnostic Technology Development Opportunities.....	80
3.2.1 What's Wrong with Microbiology	82

3.2.2 The Features Battleground of Infectious Disease Diagnostics	82
3.2.3 Multiplex vs. POC/Rapid	82
3.2.4 The Miracle of Genetics	83
3.2.5 From Multiple Pathogens to All Pathogens – The Next Next Generation	84
3.2.6 Gene Sequence Diagnostics WITHOUT the Sequencing.	84
3.2.7 Markers of Resistance.....	85
3.2.8 What Happens to the Microbiology Lab?.....	85
4. Antibiotic Resistance Diagnostics Recent Developments	86
4.1 Antibiotic Resistance Recent Developments.....	87
4.1.1 Importance of These Developments	87
4.1.2 How to Use This Section	87
Campylobacter strains exchange genes.....	87
Disinfection spreads antimicrobial resistance.....	89
Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic Platform	90
Illumina, IDbyDNA Flesh Out Sequencing-Based Respiratory Tests.....	95
Accelerate Diagnostics Announces Expansion of Antimicrobial Sensitivity Testing	101
Rapid diagnostics, antimicrobial stewardship linked to quicker time to optimal antibiotics.....	101
Visby Medical Wins AMR Diagnostic Competition	103
DNAe Technology Successfully Detects SARS-CoV-2 Sequences	103
Infections with foodborne bacteria becoming harder to treat	106
Dust is sharing antibiotic resistance genes	107
Report predicts drug resistance likely to kill 400,000.....	109

New method to test for infection resistance.....	112
Qiagen launches AMR database	114
Antibiotic resistance test for gonorrhea gets FDA breakthrough.....	115
Qiagen, Ares Genetics Ink Licensing Pact for AMR Bioinformatics	117
OpGen to File First 510(k) for AMR Gene Panel	118
Curetis' Subsidiary Ares Genetics Teams Up with Sandoz in Fight Against AMR	119
GeneCapture to determine antibiotic sensitivity in an automated rapid portable device	120
Quick identification of multidrug-resistant pathogens	122
OpGen to Offer Qiagen Nucleic Acid Purification Tech With Acuitas Pathogen Panel	124
Metagenomics Enables Researchers to Uncover Drug Resistance Genes	125
Rapid detection of multi-drug-resistant bacteria.....	127
High Throughput Manufacturing Lines to Answer Growing Needs for Diagnosis Cartridges	128
New solution for diagnosing antibiotic-resistant bacteria	130
MALDI-TOF – Results in Minutes not Days.....	131
CRISPR Tool Used to Uncover Infections.....	132
Automated Blood Tests Startup MeMed Raises Funds, Wins Grant.....	134
BD, Check-Points Receive CE Mark for Resistant Organism Screening Test	135
OpGen Inks Deal to Use Thermo Fisher PCR Tech in Acuitas Gene Panel Tests.....	136
Hospital Plumbing Harbors Antibiotic Resistant Bacteria.....	136
Curetis Gets Singapore Approval for Pneumonia Test	138

PlexBio, Denka to Codevelop Sepsis, Multidrug Resistance MDx.....	140
Curetis, MGI Collaborate to Combine Sample Prep, NGS Technologies	141
5. Key AMR Diagnostics Companies	143
1928 Diagnostics	144
Abbott Diagnostics	145
Accelerate Diagnostics	148
Beckman Coulter Diagnostics	149
Becton, Dickinson and Company	150
Binx Health.....	152
bioMérieux Diagnostics	153
Bio-Rad Laboratories, Inc.	156
Cepheid (now Danaher).....	158
Curetis N.V. / Curetis GmbH	160
Day Zero Diagnostics.	161
Enzo Life Sciences, Inc.	162
Eurofins Scientific.....	164
Fusion Genomics	167
GeneFluidics	169
Great Basin Corporation.....	170
Hutman Diagnostics	172
Inflamatix	173
Linear Diagnostics	174

Millipore Sigma	175
Ortho Clinical Diagnostics.....	176
Perkin Elmer	177
Roche Molecular Diagnostics.....	179
SeLux Diagnostics	181
Sense Biodetection.....	182
Siemens Healthineers.....	183
Sysmex	186
Thermo Fisher Scientific Inc.....	189
6. The Global Market for Antimicrobial Resistance Diagnostics.....	192
6.1 Global Market Overview by Country.....	193
6.1.1 Table – Global Market by Country	193
6.1.2 Chart - Global Market by Country	194
6.2 Global Market by Technology - Overview	195
6.2.1 Table – Global Market by Pathogen.....	195
6.2.2 Chart – Global Market by Pathogen – Base/End Year Comparison	196
6.2.3 Chart – Global Market by Pathogen – Base Year	197
6.2.4 Chart – Global Market by Pathogen – End Year	198
6.2.5 Chart – Global Market by Pathogen – Share by Year.....	199
6.2.6 Chart – Global Market by Pathogen – Segment Growth	200
6.3 Global Market by Technology - Overview	201
6.3.1 Table – Global Market by Technology	201

6.3.2 Chart – Global Market by Technology – Base/End Year Comparison	202
6.3.3 Chart – Global Market by Technology – Base Year.....	203
6.3.4 Chart – Global Market by Technology – End Year	204
6.3.5 Chart – Global Market by Technology – Share by Year	205
6.3.6 Chart – Global Market by Technology – Segment Growth	206
7. Global Antibiotic Resistance Diagnostic Markets – By Pathogen	207
7.1 Drug Resistant Streptococcus Pneumoniae - DRSP	208
7.1.1 Table DRSP – by Country.....	208
7.1.2 Chart - DRSP Growth.....	209
7.2 Drug Resistant Campylobacter - DRC.....	210
7.2.1 Table DRC – by Country	210
7.2.2 Chart - DRC Growth	211
7.3 Clostridium Difficile - CD	212
7.3.1 Table CD – by Country	212
7.3.2 Chart - CD Growth.....	213
7.4 Methicillin Resistant Staphylococcus Aureus - MRSA	214
7.4.1 Table MRSA – by Country	214
7.4.2 Chart – MRSA Growth.....	215
7.5 Drug Resistant Neisseria Gonorrhoeae - DRNG	216
7.5.1 Table DRNG – by Country	216
7.5.2 Chart – DRNG Growth.....	217
7.6 Drug Resistant Salmonella - DRNTS	218

7.6.1 Table DRNTS – by Country	218
7.6.2 Chart – DRNTS Growth.....	219
8. Global Antibiotic Resistance Diagnostic Markets – by Technology	220
8.1 Microbiology Culture.....	221
8.1.1 Table Culture – by Country	221
8.1.2 Chart – Culture Growth.....	222
8.2 Immunoassay	223
8.2.1 Table Immunoassay – by Country	223
8.2.2 Chart - Immunoassay Growth	224
8.3 PCR	225
8.3.1 Table PCR – by Country.....	225
8.3.2 Chart - PCR Growth.....	227
8.4 NGS	228
8.4.1 Table NGS – by Country	228
8.4.2 Chart - NGS Growth	229
8.5 Mass Spectrometry - MS	230
8.5.1 Table MS – by Country.....	230
8.5.2 Chart - MS Growth	231
8.6 Rapid and Point of Care – Rapid/POC	232
8.6.1 Table Rapid/POC – by Country.....	232
8.6.2 Chart - Rapid/POC Growth.....	233
9. Vision of the Future of AMR Diagnostics	234

Table of Tables

Table 1 USA - Outpatient Use of Antibiotics by Class.....	30
Table 2 USA - Outpatient Use of Antibiotics Top 5	31
Table 3 Market Players by Type.....	35
Table 4 Known Human Pathogenic Diseases	46
Table 5 The Key Market Opportunities.....	62
Table 6 - Market Potential DRSP Diagnostic	65
Table 7 - Market Potential DRC Diagnostic.....	68
Table 8 - Market Potential CD Diagnostic.....	70
Table 9 - Market Potential CD Diagnostic.....	74
Table 10 Market Potential DRNG Diagnostic	76
Table 11 Market Potential DRNTS Diagnostic.....	79
Table 12 – Key AMR Diagnostics Issues	80
Table 13 - Global Market by Region	193
Table 14 Global Market by Pathogen	195
Table 15 Global Market by Technology	201
Table 16 DRSP by Country	208
Table 17 DRC by Country.....	210
Table 18 CD by Country.....	212

Table 19 MRSA by Country.....	214
Table 20 DRNG by Country.....	216
Table 21 DRNTS by Country.....	218
Table 22 Culture by Country.....	221
Table 23 Immunoassay by Country	223
Table 24 PCR by Country	225
Table 25 NGS by Country.....	228
Table 26 MS by Country	230
Table 27 Rapid/POC by Country	232

Table of Figures

Figure 1 Pharmaceutical Spending History by Country	32
Figure 2 AMR and Antibiotic Introduction	52
Figure 3 The Death Toll of AMR	56
Figure 4 Global Market Share Chart	194
Figure 5 Global Market by Pathogen – Base vs. End Year	196
Figure 6 Global Market by Pathogen Base Year	197
Figure 7 Global Market by Pathogen End Year	198
Figure 8 Pathogen Share by Year	199
Figure 9 Pathogen Segment Growth	200
Figure 10 Technology - Base vs. End Year Segment Shift	202
Figure 11 Technology Market Base Year	203
Figure 12 Technology Market End Year	204
Figure 13 Technology Share by Year	205
Figure 14 Technology Segment Growth	206
Figure 15 DRSP Growth	209
Figure 16 DRC Diagnostics Growth	211
Figure 17 CD Growth	213
Figure 18 MRSA Growth	215
Figure 19 DRNG Growth	217

Figure 20 DRNTS Growth.....	219
Figure 21 Culture Growth.....	222
Figure 22 Immunoassay Growth.....	224
Figure 23 PCR Growth	227
Figure 24 NGS Growth.....	229
Figure 25 MS Growth	231
Figure 26 Rapid/POC Growth	233